However, it is essential for policymakers, authorities officials, and health care practitioners engaged in HCV testing, care, and treatment to be aware that the overall performance of individual RDTs for detection of HCV Ab vary widelyJune 19, 2022
However, it is essential for policymakers, authorities officials, and health care practitioners engaged in HCV testing, care, and treatment to be aware that the overall performance of individual RDTs for detection of HCV Ab vary widely. for each study and pooled statistics, along with 95% confidence intervals . We pooled test estimations using the DerSimonian-Laird method, a bivariate random effect model. We did further subanalyses based on research standard (EIA only; NAT or immunoblot; EIA, NAT, or immunoblot), brand, sample type, and combination test. We performed all statistical analysis (including heterogeneity, through Q test) using the software R and RevMan 5.3. Results Study selection A total of 11,163 citations were recognized, and 6163 duplicates were removed. Each of the 5000 unique citations was examined. A total of 52 research studies were included in the final analysis (Fig.?1) [8, 16, 19C68]. Of the 52 studies, 32 studies evaluated the accuracy of 30 different quick diagnostic checks (RDTs) [19C50], of which 5 evaluated RDTs compared to EIA only [25, 26, 31, 34, 49], 13 compared RDT results to NAT or immunoblot [19C22, 27, 29, 32, 37, 42, 43, 45, 47, 50], and 14 focused on evaluating RDT by comparing with the results of EIA or immunoblot or NAT [23C26, 30, 34, 35, 38, 39, 41, 44, 48, 49, 51]. Eleven studies evaluated the diagnostic accuracy of oral fluid RDTs [22, 24, 27, 29, 33, 34, 43C45, 47, 52]. Open in a separate LAQ824 (NVP-LAQ824, Dacinostat) windowpane Fig. 1 LAQ824 (NVP-LAQ824, Dacinostat) PRISMA circulation diagram outlining study selection analyzing the diagnostic accuracy of HCV antibody checks There were insufficient data to undertake a subanalysis based on HIV co-infection or additional co-infections. Study characteristics Of the 52 included studies, nine were published before 2000 [37, 38, 42, 53C58], 12 studies reported evaluation using oral fluid samples, and 34 studies evaluated POC tests. Of the 52 studies, 41 different brands of screening kits were evaluated (Table?1). Assessment of the quality of the studies All studies used a cross-sectional or caseCcontrol design. KPSH1 antibody The risk of bias in individual selection, index test, or research standard was assessed using QUADAS-2 (Table?2). Among the included studies, 25 experienced at least one category that was regarded as high risk [19, 22, 25C28, 30, 31, 34, 36C39, 41, 45C50, 53, 55, 56, 58C62]. The risk of bias in individual selection usually came from a poor description of individual selection and medical scenario. Bias in the index test was primarily due to a lack of reported blinding while reading test results. Bias in the research standard was due to the use of multiple research requirements (EIA, NAT, and/or immunoblot). Bias in LAQ824 (NVP-LAQ824, Dacinostat) the circulation and timing was primarily due to a lack of reported details. Table 2 Quality assessment by QUADAS-2 of the included studies low risk, high risk, unclear risk Diagnostic accuracy Overall clinical overall performance of assaysThe 52 included studies contributed 127 data points from 52,273 unique test measurements. Some studies contributed additional LAQ824 (NVP-LAQ824, Dacinostat) data points by comparing the accuracy of two or more checks, reporting data from multiple study sites, or reporting the accuracy of a test in more than one type of specimen. The sample sizes of the included studies ranged from 37 to 17,894. Sensitivities of included studies ranged LAQ824 (NVP-LAQ824, Dacinostat) from 22 to 100%, and specificities ranged from 77 to 100%. The overall pooled level of sensitivity and specificity for those tests were 97% (95% CI: 97%C98%) and 99% (95%.